SyntheMed Appoints Corinne Mundin as Director, International Market D... ( ISELIN N.J. July 18 /- SyntheMed ...)

SyntheMed Appoints Corinne Mundin as Director, International Market Development

Date:7/18/2008

ISELIN, N.J., July 18 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today the appointment of Ms. Corinne Mundin to the newly-created position of Director, International Market Development. Ms. Mundin, who is based in England, brings more than 20 years of sales, sales management and market development experience in the medical device industry including 10 years in the cardiac surgery product segment. Most recently, she served as Director of International Sales for Novadaq Technologies Inc., a diagnostic equipment company focused on cardiac surgery, and held previous international sales management positions with Chase Medical LLP and Guidant CVS. Ms. Mundin's responsibilities will include enhancing the company's distributor network, establishing corporate relationships with key accounts, and increasing surgeon awareness of the benefits that REPEL-CV(R) Adhesion Barrier, the company's novel anti-adhesion product, can provide in reducing adhesion formation after open heart surgery.

Marc R. Sportsman, SyntheMed's vice president of sales, stated, "We are extremely pleased that Corinne has joined the SyntheMed team and we are confident she will positively impact our sales growth in European and other international markets. Her experience and knowledge of international medical device markets will be critically important as we continue our efforts to establish and improve our distribution channels and increase market penetration."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surround tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
2. SyntheMed to Present at 2007 Lazard Capital Markets Fourth Annual Healthcare Conference
3. SyntheMed, Inc. Adopts Shareholder Rights Plan
4. WorldHeart Appoints David Pellone Chief Financial Officer
5. Novo Nordisk Appoints New Leader of North American Business
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. Resonant Medical Appoints New Vice President of Global Sales
9. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development

Post Your Comments:

SyntheMed Appoints Corinne Mundin as Director, International Market D...( ISELIN N.J. July 18 /- SyntheMed ...),Health